TRT Aveed denied as non-formulary by Humana?

Humana's specific coverage criteria for trt aveed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Aveed as Non-Formulary

A non-formulary denial means Aveed (testosterone undecanoate long-acting injection) is not on Humana's current covered drug list for your plan, or is placed on a tier that requires additional approval. Humana's formulary includes several testosterone formulations, and their system defaults to formulary alternatives — typically lower-cost gels, patches, or short-acting injections — before approving a non-formulary agent.

## Why This Denial Is Appealable

Formulary exclusions are not final. You can appeal on two grounds: (1) a formulary exception (medical necessity for the specific non-formulary drug when alternatives are clinically inadequate), or (2) a standard internal and external appeal challenging whether the formulary design is being applied correctly. Formulary exception processes exist under both ACA and Medicare Part D rules specifically to protect patients who cannot use the formulary alternatives.

## Federal Appeal Framework

• Formulary exception request: Submit with prescriber documentation of why formulary alternatives are medically inappropriate for this patient. Humana must respond within 72 hours (standard) or 24 hours (expedited).
• Internal appeal: If the exception is denied, file a formal internal appeal within 180 days. Humana must respond within 30 days (standard) or 72 hours (expedited).
• External review (ACA §2719): After the internal appeal is exhausted, you have approximately 4 months to request binding independent external review.

## Documentation to Gather

1. Formulary alternative trial history — For each testosterone formulation on Humana's formulary that was tried, document: the product name, start/stop dates, reason for failure or discontinuation (inadequate response, intolerability, compliance barrier), and prescriber notes. 2. Clinical reason Aveed is necessary — Aveed's long-acting injectable formulation offers a specific pharmacokinetic profile distinct from daily or weekly alternatives. The prescriber letter must explain the clinical rationale for choosing this formulation for this patient — such as documented adherence failure with daily formulations, absorption issues with transdermal routes, or clinical preference for in-office administration under the Aveed REMS program. 3. Diagnosis and severity documentation — Chart confirmation of hypogonadism diagnosis and current clinical status. 4. Prescriber medical-necessity letter — Explicitly addresses why formulary alternatives are inadequate and why Aveed is the medically necessary choice. Should reference the FDA-approved label and relevant Endocrine Society guidance. 5. Humana formulary and exception policy — Obtain from Humana's website or member portal. Verify the formulary tier and exception process applicable to your plan year.

## Criteria-Mapping Structure

| Exception Criterion | Documentation | |---|---| | Formulary alternative tried | [Product, dates, outcome — from chart] | | Clinical reason alternative failed/inappropriate | [Chart note + prescriber explanation] | | Medical necessity for Aveed specifically | [Prescriber letter rationale] |

Note: For Medicare Advantage plans administered by Humana, formulary exception and appeal rights follow CMS Medicare Part D rules, which carry their own timelines and escalation paths to the Medicare Independent Review Entity (IRE). Confirm your plan type with Humana before filing.